^
    Back
    Association details:
    Biomarker:BRCA1 mutation
    Cancer:Pancreatic Ductal Adenocarcinoma
    Regimen: (5-fluorouracil + irinotecan + leucovorin calcium + oxaliplatin)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2018
    Title:

    Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic ductal adenocarcinoma patients treated with FOLFIRINOX

    Published date:
    10/09/2018
    Excerpt:
    Mutations were seen in BRCA1 (N = 7), BRCA2 (N = 5), BRCA1/2 (N = 3), PALB2 (N = 3), MSH2 (N = 1) and FANCF (N = 1) of all the DDR genes sequenced...Cox regression (HR 0.37 [0.15-0.94], p = 0.04) showed presence of DDRGM was associated with improved OS....we found that the presence of germline and somatic DDRGM as well as germline BRCA1/2 mutations are associated with improved OS in PDAC patients treated with FOLFIRINOX.
    DOI:
    10.1093/annonc/mdy282.100
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    BMJ Case Rep
    Title:

    Response in BRCA1 mutation carrier with metastatic pancreatic adenocarcinoma treated with FOLFIRINOX

    Published date:
    04/29/2022
    Excerpt:
    A woman in her 50s...was diagnosed with stage IV pancreatic ductal adenocarcinoma (PDAC) metastatic to the liver and was found to harbour a BRCA1 germline mutation. She had palliative chemotherapy, initially with 5-fluorouracil, leucovorin, irinotecan and oxaliplatin, and then FOLFIRI and capecitabine, achieving a sustained near-complete response for at least 86 months.
    Secondary therapy:
    FOLFIRI + capecitabine
    DOI:
    http://dx.doi.org/10.1136/bcr-2022-249370